
Index

Page references followed by b denote boxes; those followed by f denote figures; those followed by t denote tables.

A

- ACC (acetyl-CoA carboxylase), 105, 107, 109f, 113, 115, 117, 173
- Acetate, 182, 193
- Acetoacetate, 116b, 117b
- Acetone, 116b, 117b
- Acetylation, 181–183, 184f
- acetyl-CoA and, 9, 10f, 181–183, 184f
 - of lysine residues, 2, 183
- Acetyl-CoA, 2
- allosteric regulation of pyruvate carboxylase, 93
 - from citrate, 43, 53, 56f, 59, 60f, 71, 72f, 107, 108f
 - citrate transporter and, 53–54, 56f
 - entry into TCA cycle, 41, 42f
 - in fatty acid synthesis, 107–110, 108f–109f
 - generation of, 39, 41, 42f, 43, 45, 45f, 53–54, 56f, 59
 - metabolic functions, 9, 10f, 53
 - posttranslational modifications and, 181–183, 184f
- Acetyl-CoA carboxylase (ACC), 105, 107, 109f, 113, 115, 117, 173
- Acetylserotonin *O*-methyltransferase, 139, 140f
- Aconitase, 60, 70
- Activation energy, 13, 13f, 18
- Active site, 20
- Acylglycerophosphate acyltransferase, 110, 111f
- ACYL (ATP-citrate lyase), 53, 56f, 59, 71, 72f, 107, 108f, 182, 192
- Acyl-CoA synthetase, 110
- Acyl transacylase, 107, 109f
- Adenine, 148, 149f, 155, 157f.
- See also* Purines
- Adenine nucleotide transporter (ANT), 38, 47f, 53, 56–57
- Adenosine, 142, 143f, 164–165, 164f
- Adenosine deaminase, 165
- Adenosine phosphoribosyltransferase (APRT), 155, 157f
- Adenylate kinase, 16, 32, 112, 152, 154f
- Adenylosuccinate, 152, 154f–155f
- ADP
- adenine nucleotide transporter (ANT), 38, 47f, 53, 56–57
 - adenylate kinase reaction, 16, 32, 112
 - energy charge, 18
 - P2 purinoreceptor activation, 164, 164f
- Aerobic glycolysis, 34–35, 190, 220
- Aging
- free radical theory of, 83b
 - metabolism and, 212
- AKT, 120, 168f, 169–170, 199
- Alanine
- β -alanine, 161–162, 163f
 - conversion to pyruvate, 93
 - generation of, 130, 132f
 - from pyruvate, 26
 - urea cycle and, 134
- Alanine aminotransferase, 134
- Albinism, 41
- Alcohol dehydrogenase, 31f

- Aldolase B, 100, 101f
Aldosterone, 121, 122f
Allopurinol, 156f, 157b
Allosteric enzymes, 20
Allosteric regulation, 26, 27f, 32, 45, 93
Allosteric site, 20, 21
 α -ketoglutarate
 amino acid generation from, 130, 132f, 134
 from cystathionine, 142, 143f
 from glutaminolysis, 39, 44, 44f, 45, 59, 94–95
 isocitrate conversion to, 70, 71f
 in TCA cycle, 39, 42f–45f, 43–45, 59–60, 60f
 α -ketoglutarate dehydrogenase, 41, 42f, 45, 45f, 77
 α -ketoglutarate-dependent dioxygenase family,
 4–5, 177, 186, 203, 221
 α -proteobacteria
 endosymbiont theory and, 37
 proton pumps, 47
Amino acids, 127–145
 arginine metabolism, 129, 144, 145f
 conversion to TCA cycle intermediates, 132,
 133f
 cysteine production, 142, 143f, 144
 degradation, 131–136, 133f, 135f, 137f
 epigenetics and, 142
 essential, 127, 128f, 129
 feeding into TCA cycle, 39
 methionine metabolism, 128, 142–144, 143f
 for neurotransmission, 138–140, 139f–141f
 overview of metabolism, 128f
 production of nonessential, 129–131, 130f–132f
 quick guide, 127–129, 128f
 tryptophan metabolism, 129
 tyrosine metabolism, 128, 129, 139–142, 141f
4-Aminobutyrate aminotransferase, 138, 139f
Amino sugars, 26, 27f
Ammonium ions, 128, 130, 131, 132f–133f, 134
AMP
 from adenine, 156, 157f
 cAMP, 95, 97b, 162
 catabolism, 152, 156f
 energy charge, 18
 increasing levels of, 16, 32, 45, 61, 95, 156, 172
 from inosine 5'-monophosphate, 152, 154f
 PFK1 regulation, 32
 regulation of gluconeogenesis, 95, 96f
AMP-activated protein kinase (AMPK)
 activation of, 16, 172–173, 173f, 181
 autophagy regulation, 177
 in cancer cells, 200
 catabolism induction by, 61, 172–173,
 173f–174f
 cholesterol regulation, 121, 123
 fatty acid regulation, 117
 metformin and, 2, 209b
 nutrient sensing, 216–217
 salicylate inactivation of, 120
 SIRT1 phosphorylation by, 184
Amphibolic pathway, 41
Amylo-(1,4–1,6)-transglycosylase, 96
Anabolism
 aberrant activation of signaling pathways in
 proliferating cells, 197–203,
 198f–199f, 201f
 acetyl-CoA role in, 10f
 entropy change in anabolic reactions, 11
 overview, 1, 2f, 9
Anaerobic glycolysis, 31
Analyzing metabolism, 223–231
Anaplerosis, 43–44
Anemia, 68, 70b
Angiogenesis, 202
ANT (adenine nucleotide transporter), 38, 47f, 53,
 56–57
Antimetabolite drug, 206
Antioxidants, 207, 209
Antiporters, 58
Apoptosis, 58
APRT (adenosine phosphoribosyltransferase),
 155, 157f
Archaea
 endosymbiont theory and, 37
 proton pumps, 47
Arginase, 134, 137f
Arginine
 L-arginine, 144, 145f
 nitric oxide production, 144, 145f
 in urea cycle, 129, 134, 136b, 137f
Arginosuccinase, 134, 137f
Arginosuccinate, 134, 137f
Arginosuccinate synthetase, 134, 137f
Artificial sweeteners, 101b
Asparagine, 130
Asparagine synthetase, 130, 132f
Aspartate, 43, 44f
 in pyrimidine biosynthesis, 158, 159f
 urea cycle and, 134, 135f, 136, 137f
Aspartate aminotransferase, 130, 132f, 134
Aspartate transcarboxylase, 158
Aspirin, 2
Atkinson, Daniel, 18
ATM, 218
ATP, 9, 11
 adenine nucleotide transporter (ANT), 38, 47f,
 53, 56–57
 allosteric regulation of TCA cycle, 45

- amount generated by complete oxidation of
 glucose, 54–55, 57f
discovery of, 24b
energy charge, 18
extracellular as signaling molecule, 162, 164, 164f
generation
 in amino acid degradation, 132, 134
 in cancer cells, 198, 202
 in glycolysis, 23, 24, 25f, 26
 in lipid catabolism, 111–113
 in NADH and FADH₂ oxidation, 51
 in proliferating cells, 193
oxidative phosphorylation, 38, 39, 46–51, 47f
production by adenylate kinase, 16, 32
production in mitochondria, 23, 26, 38–39, 41
for proliferating cell metabolic needs, 189–190,
 189f
respiratory rate controlled by, 55–57
uncoupling biosynthetic activity from ATP
 generation in mitochondria, 58–60, 60f
 use in glycolysis, 29
ATP-citrate lyase (ACLY), 53, 56f, 59, 71, 72f,
 107, 108f, 182, 192
ATP-coupled reaction, 15–16, 15f
ATP synthase, 39, 46, 47f, 49
Autoimmunity, 215
Autophagosome, 175–176, 175f
Autophagy, 167, 174–177, 175f–176f
- B**
- Beclin 1 interacting complex, 175–176, 176f
Beer, 31
β-alanine, 161–162, 163f
β-aminoisobutyrate, 161–162, 163f
β-hydroxybutyrate, 116b, 117b
Betaine-homocysteine S-methyl transferase, 142,
 143f
β-ketoacyl carrier protein reductase, 107, 109f
β-ketoacyl synthase, 107, 109f
β-oxidation, 103, 105, 111, 113, 114f
Bicarbonate, 90
Bile acid, 121
Biochemistry, defined, 7
Biosynthesis
 biosynthetic capacity of glycolytic
 intermediates, 24, 26, 27f, 29, 32, 35
 NADPH and, 65, 66
 TCA cycle as biosynthetic hub, 42–44, 43f
 uncoupling biosynthetic activity from ATP
 generation in mitochondria, 58–60, 60f
Biotin, 90
1,3-Bisphosphoglycerate, 25f, 26, 27f, 29, 93
2,3-Bisphosphoglycerate, 25f, 26, 27f
Body mass index (BMI), 103
Bond energy, 11, 12, 14
Branching enzyme, 96, 98f
Breast cancer, 100, 205
Brown, Michael, 124–125
Brown fat cells, uncoupled respiration in, 49
Butyric acid, 105, 106f
- C**
- Caffeine, 165b
Calcium
 AMP-activated protein kinase (AMPK)
 activation, 173, 173f
 homeostasis regulation by mitochondria, 57–58,
 59f
 stimulation of TCA cycle by, 45–46, 45f
Calorie, 11
cAMP, 95, 97b, 162
cAMP-dependent protein kinase A (PKA), 95, 97b
Cancer. *See also* Cancer metabolism
 aberrant activation of signaling pathways,
 197–203, 198f–199f, 201f
 breast, 100, 205
 genetic alterations driving tumorigenesis,
 203–206, 204f
 glucose metabolism in cancer cells, 34–35, 34f
 hyaluronic acid expression in breast cancer stem
 cells, 100
 hypoxia and, 202–203
 metabolic plasticity, 206
 metformin as anticancer agent, 208b–209b, 208f
 non-small cell lung cancer, 206
 prostate, 231
 therapeutic targets, 206–209, 220–221
 Warburg effect, 190, 231
Cancer metabolism, 4–5
 fructose metabolism by tumor cells, 100b
 future perspectives, 213–214
 glucose metabolism, 34–35, 34f
 heterogeneity of, 197, 199, 206
 modern understanding of, 219–220
 oncometabolites, 226
 one-carbon metabolism, 73, 205
 rebirth of, 218–219
 as therapeutic target, 206–209, 220–221
Carbamoyl phosphate, 134, 135f, 137f, 158, 159f
Carbamoyl phosphate synthetase I, 134, 137f
Carbamoyl phosphate synthetase II, 158, 160, 162f
Carbohydrate response elements, 180–181, 180f
Carbohydrates, 85–101
 complex, 85

- Carbohydrates (*Continued*)
 metabolism of simple sugars, 87–90, 87f–89f
 overview of metabolism, 86f
 quick guide to, 85, 87
 signaling and, 87, 97–100
- Carbon
 carbon substrate, cell choice of, 213
 isotope tracing, 227–231, 228f
- Carbon dioxide, release in TCA cycle, 41, 42f, 55
- Carbonyl cyanide-*p*-trifluoromethoxyphenyl-
 hydrazone (FCCP), 49, 50b, 58
- Carnitine-acylcarnitine translocase, 103, 112f, 113
- Carnitine acyltransferase I (CPTI), 103, 105, 112f,
 113, 117
- Carnitine acyltransferase II (CPTII), 103, 112f, 113
- Carnitine transport cycle, 103, 112f, 113
- Catabolism
 acetyl-CoA role in, 10f
 AMPK induction of, 172–173, 173f–174f
 entropy change in catabolic reactions, 11
 lipid, 111–113, 114f
 overview, 1, 2f, 9
 purine, 152, 156f
 pyrimidine, 160–162, 163f
- Catalase, 74f, 75, 80
- Catalysts, enzymes as, 9–10, 13, 18–20
- Catecholamines, 140, 141f
- CD44, 100
- Cell death, 58
- Cells
 carbon substrate, choice of, 213
 energetic state of, 16, 18
 energy transformation in, 24b
 mitochondria number in, 29, 68
- Cell signaling. *See* Signaling
- Cellular respiration, factors controlling, 55–57
- Cellulose, 85
- Ceramide, 120
- cGMP, 144, 145f, 162
- Chance, Britton, 55
- Chaperone-mediated autophagy, 175
- Chavez, Cesar, 116b
- Chemiosmotic theory, 46–48, 48b, 51
- Cholesterol
 reduction with statins, 124b, 124–125
 regulation of cellular levels, 121, 123–125
 synthesis, 120–121, 122f
- ChREBP, 180–181, 180f
- Chronic obstructive pulmonary disease, 186
- Citrate
 conversion to acetyl-CoA and oxaloacetate, 43,
 53, 56f, 59, 60f, 107, 108f
 fatty acid metabolism regulation, 113, 115
 generation by glutamine-dependent reductive
 carboxylation, 60, 60f
 from glutamine-dependent reductive
 carboxylation, 203
 in TCA cycle, 39, 41, 42f, 43, 43f, 45
 transport into cytosol, 43, 53–54, 54f, 59, 107,
 108f, 192
- Citrate synthase, 41, 42f, 45, 45f
- Citrate transporter, 53–54, 54f
- Citric acid cycle. *See* TCA cycle
- Citrulline, 134, 136b, 137f, 144, 145f
- Coenzymes, 19
- Cofactors, 19
- Common cold, 82
- Competitive inhibition, 20, 21f
- Concentration, affect on reaction rate, 19–20, 20f
- Conservation of energy, law of, 10
- Control coefficient, respiratory rate, 57
- Cori, Carl and Gerty, 92b
- Cori cycle, 90, 92b, 192
- Cortisol, 121, 122f
- Coupled reactions, 15–16, 15f, 17b–18b
- Coupled respiration, 49, 50b
- Covicine, 70b
- CPTI (carnitine acyltransferase I), 103, 105, 112f,
 113, 117
- CPTII (carnitine acyltransferase II), 103, 112f, 113
- Crabtree effect, 31
- Crick, Francis H.C., 147
- Cristae, 38
- CTP, 159, 160f–161f
- CTP synthetase, 159, 160f–161f
- Currency exchange, 51
- Cyclooxygenase enzymes, 120
- Cystathionine, 129, 142, 143f
- Cystathionine β synthase, 129
- Cystathionine- γ -lyase, 129, 142, 143f
- Cysteine, 80–81
 glutathione from, 129, 143f, 144
 production, 129, 142, 143f, 144
 thio group, 76
- Cystine, 144, 195
- Cytochrome *c*, 39, 46, 52
- Cytochrome *c* oxidase, 39, 178
- Cytochrome *c* reductase, 39
- Cytosine, 149f, 150. *See also* Pyrimidines

D

- Deacetylation, 183–184, 184f
- Debranching enzyme, 96, 98f
- Decarboxylation, oxidative, 41
- de Duve, Christain, 174

- de Hevesy, György, 226
δ-aminolevulinic acid, 129, 131f
δ-aminolevulinic acid synthase, 129, 131f
δ-pyrroline-5-carboxylate, 131, 132f
Demethylation, 4, 185–186
Deoxyribonucleotides, 150–151, 150f
Diabetes, 208b, 225
Diacylglycerol acyltransferase, 110, 111f
Diacylglycerols, 110, 111f, 120
Diet, metabolism and, 211–212
Diet soda, 101b
Dihydrofolate, 160
Dihydrofolate reductase, 160
Dihydroxyacetone phosphate, 25f, 26, 27f, 29, 90, 94, 100b, 101f
2,4-Dinitrophenol (DNP), 50
Disaccharides, 85, 87
Disease
 integration of metabolism with diet and environment, 211–212
 metabolic disease, screening for, 225–226
 metabolism linked to, 2, 4f
 mitochondria and, 62–63
Disulfide bond, 76
Disulfide glutathione (GSSG), 76, 81, 82f
DNA, 148, 150
 deoxyribonucleotides, 150–151, 150f
 mitochondrial (mtDNA), 38, 61, 62
DNP (2,4-dinitrophenol), 50
Dopamine, 139–140, 141f
Dopaquinone, 139, 141f
Double bonds, in fatty acids, 105, 106f
Dual oxidases, 78
- E**
- Easter Island, 172b
Eicosanoids, 119–120, 119f
Electrons, flow of, 214–215
Electron transport chain (ETC)
 ATP amount generated by, 51
 complexes, 39, 40f, 46, 47f, 48–53
 efficiency of electron transfer, 51–52
 NAD⁺ regeneration by, 30, 31, 46
 overview of, 39
 oxidative phosphorylation, 38, 39, 46–51, 47f
 respiratory rate control by, 57
 ROS generation, 51–52, 76–77, 77f, 179–180
Emden, Gustav, 24b
Emden-Meyerhof-Parnas pathway, 23.
 See also Glycolysis
Endergonic reaction, 12, 12f, 15–16
Endo, Akira, 124b
Endoplasmic reticulum, ROS generation, 78, 80f
Endosymbiont theory, 37
Endothelial cells, ATP generation in, 193
Endothelium-derived relaxing factor, 144
Energy
 change in reactions, 9–16
 conservation of, 10
 thermodynamics, 10–11
Energy charge, 18
Enoyl-ACP reductase, 107, 109f
Enthalpy, 11
Entropy, 11
Environment, metabolism and, 211–212
Enzymes
 activation energy lowered by, 13, 13f, 18
 allosteric, 20
 as catalysts, 9–10, 13, 18–20
 cofactors, 19
 control of metabolic flux of pathways by, 21–22
 genetic alterations driving tumorigenesis, 203–206, 204f
 glycolytic, regulation of, 31–34, 33f
 isoforms, 218
 posttranslational modifications, 219
 reaction rate and, 13, 18–20, 20f
 regulation, 20–21, 21f
 ribozyme, 18
Enzyme–substrate complex, 19, 20
Epigenetics, 2, 5, 9
 amino acids and, 128, 142
 oxygen levels and, 186
 threonine metabolism and, 185
Epinephrine, 140, 141f, 142
Equilibrium constant (K_{eq}), 14–15
ERK, 169
Essential amino acids, 127
ETC. *See* Electron transport chain
Ethanol, from fermentation, 31, 31f
Eukaryote, evolution of first, 37
Eumelanins, 41
Evolution, 1, 23, 37
Exergonic reaction, 12, 12f, 15–16, 23
- F**
- FAD, as coenzyme, 41
FADH₂
 ATP amount generated in oxidation by ETC, 51–55
 coupled reactions, 16
 electron transport chain and, 39, 40f, 46, 47f, 49, 51

- FADH₂ (*Continued*)
generated
 in fatty acid oxidation, 113, 114f
 in TCA cycle, 39, 41, 42f
glycerol-phosphate shuttle and, 53, 55f
Fan, Teresa, 229
Farnesyl pyrophosphate, 121, 122f
FASN, 107
Fasting, ketone body production with, 116b–117b
Fats. *See* Lipids
Fatty acids. *See also* Lipids
 double bonds in, 105, 106f
 regulation of anabolism and catabolism, 105, 113, 115, 115f, 117
 structure, 105–107, 106f
 synthesis, 103, 105–110, 108f–109f, 111f
 transport, mitochondrial, 103, 111–113, 112f
 unsaturated and saturated, 105, 106f, 107
Fatty acid synthase, 107, 109f, 110
Fatty acyl-CoA, 112–113, 112f
Fatty acyl-CoA synthetase, 111–112
Favism, 70b
FCCP (carbonyl cyanide-*p*-trifluoromethoxyphenylhydrazine), 49, 50b, 58
Fed-fast cycle, 97b
Feedback inhibition, 20, 32
Feed-forward activation mechanism, 32
Fermentation
 homolactic, 31
 in mammals and yeast, 31, 31f
 Pasteur effect, 31
Fialuridine, 62
Final electron acceptor, 46, 47f
Fischer, Hermann Emil, 165b
FKBP12, 169–170
5-Fluorouracil, 160
Folate, 72–74, 73f, 142, 143f, 205
F₁-ATPase, 49, 51
F₁F₀-ATP synthase (F₁F₀-ATPase), 39, 49
Formate, 73, 73f
Franklin, Rosalind, 147
Free radical theory of aging, 83b
Fructokinase, 89, 89f, 100
Fructose
 entry into glycolysis, 100b, 101f
 metabolism, 89–90, 89f, 100b–101b, 101f
 obesity epidemic and, 90, 100b
 structure, 87f
 sweetness, 88
 transporter, 100b
Fructose 1,6-bisphosphatase, 32, 33f, 94, 95, 96f, 97b
Fructose 1,6-bisphosphate, 29
Fructose 2,6-bisphosphate, 29, 95, 96f
Fructose 2,6-bisphosphatase-3, 68
Fructose 1-phosphate, 89, 89f, 100b, 101f
Fructose 6-phosphate
 in glycolysis, 25f, 26, 27f
 in pentose phosphate pathway, 67f, 68, 69f
Fructose 1-phosphate aldolase B, 89f, 90
Fructose 6-phosphate amidotransferase, 193
Fuel choice, cellular, 213
Fuel switches, 213
Fumarase, 136
Fumarate, 46, 134, 136, 137f, 156–167, 158f, 203–204
Fumarate hydratase, 202–204, 204f
Furchgott, Robert F., 144
Future pathways of metabolism research, 211–221
- G**
- GABA (γ -aminobutyric acid), 129, 138, 139f
Galactokinase, 88, 88f
Galactose
 catabolism, 88–89, 88f
 conversion to glucose 6-phosphate, 88–89
 structure, 87f
Galactose-1-P-uridyl transferase, 88, 88f
GalNAc (*N*-acetylgalactosamine), 97–98
 γ -aminobutyric acid (GABA), 129, 138, 139f
 γ -glutamyl kinase, 130, 132f
Gandhi, Mahatma, 116b
GCN2, 216–217
Gene expression, 1–2, 9, 217–218
Genetic alterations driving tumorigenesis, 203–206, 204f
Gerszten, Robert, 225
GFAT (glutamine fructose 6-phosphate amidotransferase), 98, 99, 99f
Gibbs, Josiah Willard, 11
Gibbs free energy, 11–16, 18
 in glycolytic reactions, 27–29, 28f, 28t
 in TCA cycle reactions, 41, 44–45
GlcNAc (*N*-acetylglucosamine), 97–100
Global profiling, 226
Glucagon, 32, 95, 97b
Glucocorticoids, 121
Glucokinase, 32
Gluconeogenesis, 28, 32, 43–44, 68, 90–95, 91f
 blood glucose levels maintained by, 90
 as endergonic process, 94
 enzymes shared with glycolysis, 91f
 location of, 90
 overview, 85–86
 regulation of, 95, 96f
 sources of carbons for, 90–95, 94f

- Glucosamine 6-phosphate, 98, 99f, 193
Glucosamine 6-*P*-N-acetyltransferase, 98, 99f
Glucose
 ATP amount generated by complete oxidation of, 54–55, 57f
 blood concentration of, 27, 90
 cancer metabolism, 34–35, 34f, 198
 carbon isotope tracing, 227
 Crabtree effect, 31
 fructose metabolism compared, 100b–101b
 in glycolysis, 23, 25f, 27f, 88
 glycosylation of growth factors, 186–187
 homeostasis
 during fed-fast cycle, 97b
 glycogen synthesis and degradation, 95–97, 97b
 inhibition of metabolism as cancer therapy, 207
 phosphorylation, 29
 structure, 87f
 transcriptional network regulation, 180–181, 180f
Glucose 6-phosphatase, 94, 97
Glucose 1-phosphate, 96–97, 98f
Glucose 6-phosphate
 conversion from glucose 1-phosphate, 97
 galactose conversion to, 88–89
 in glycolysis, 25f, 26, 27f, 88
 hexokinase inhibition, 32
 in pentose phosphate pathway, 65, 66, 67f, 68, 69f
Glucose 6-phosphate dehydrogenase
 deficiency, 68, 70b
 in pentose phosphate pathway, 67f, 68
Glucose transporters, 194, 195f
Glutamate, 39, 43–44, 43f, 44f, 60, 128
 amino acid generation from, 130, 132f
 glutathione from, 129
 glycosylation of growth factors, 186–187
 neurotransmission and, 129, 138, 139f
 transporters, 194–195, 195f
 urea cycle and, 134, 135f
Glutamate-cysteine ligase, 144
Glutamate dehydrogenase, 130, 132f, 134
Glutamate 5-phosphate, 130, 132f
Glutamic acid decarboxylase, 138, 139f
Glutaminase, 132f, 134, 135f
Glutamine, 5, 39, 43–44, 44f, 60, 60f
 fuel for cancer cells, 198
 inhibition of metabolism as cancer therapy, 207
 in proliferating cells, 193
 transporters, 194–195, 195f
 urea cycle and, 134, 135f
Glutamine-dependent reductive carboxylation, 60, 60f, 203
Glutamine fructose 6-phosphate amidotransferase (GFAT), 98, 99, 99f
Glutamine gluconeogenesis, 94–95
Glutamine synthetase, 130, 132f, 134
Glutaminolysis, 39, 44, 44f, 45, 59, 94–95, 193
Glutaredoxins (GRXs), 76
Glutathione (GSH), 65, 66, 81, 129, 144
Glutathione peroxidases (GPXs), 74f, 75, 80–82, 82f
GLUT5 transporter, 100b
Glycans, 97
Glyceraldehyde, 90
Glyceraldehyde 3-phosphate
 dihydroxyacetone phosphate converted to, 100b, 101f
 in gluconeogenesis, 91f, 93
 in glycolysis, 24, 25f, 26, 29
 in pentose phosphate pathway, 67f, 68, 69f
Glyceraldehyde 3-phosphate dehydrogenase, 29, 53, 54f, 77, 93
Glycerol
 in gluconeogenesis, 94
 in lipids, 105, 110
Glycerol kinase, 94
Glycerol 3-phosphate, 26, 27f, 94, 110, 111f
Glycerol 3-phosphate acyltransferase, 110, 111f
Glycerol 3-phosphate dehydrogenase, 53, 55f, 94
Glycerol–phosphate shuttle, 53, 55f
Glycine, 72–73, 73f
 glutathione from, 129
 in heme synthesis, 129, 131f
 as neurotransmitter, 129
 from 3-phosphoglycerate, 129, 130f
 S-adenosylmethionine (SAM) generation, 185
Glycine decarboxylation, 205–206
Glycoconjugates, 85
Glycogen, 26, 85, 87
 degradation, 96–97, 98f
 glucose homeostasis and, 95–97, 97b
 synthesis, 95–96, 98f
Glycogenolysis, 90, 96–97, 98f
Glycogen phosphorylase, 96–97, 97b, 98f
Glycogen synthase, 95, 97b, 98f
Glycolipid, 85
Glycolysis
 aerobic, 34–35, 190, 220
 anaerobic, 31
 ATP-coupled reactions, 15–16, 15f
 ATP use in, 29
 biosynthetic capacity of glycolytic intermediates, 24, 26, 27f, 29, 32, 35

- Glycolysis (*Continued*)
in cancer cells, 200, 201f, 202
control by pyruvate kinases, 5
energy-generating capacity of, 24–26, 25f
entry of simple sugars into, 88–90, 88f–89f
enzymes shared with gluconeogenesis, 91f
evolution of, 23
fructose entry into, 100b, 101f
Gibbs free energy change in, 27–29, 28f, 28t
irreversible reactions, 31–32, 87, 90
lipid synthesis and, 105, 111f
major features of, 23–24
metabolic flux quantification, 229
origin of term, 23
overall reaction, 23
in proliferating cells, 190, 191f, 192, 196–197
regulation, 31–34, 33f
steps in, 23, 24, 25f, 87
- Glycolytic intermediates
amino acids from, 129, 130f
biosynthetic capacity of, 24, 26, 27, 29, 32, 35
NADPH generation from, 65, 66, 67f, 68, 69f
- Glycoproteins, 85, 97–100, 99f
- Glycosidic bonds, 95, 97
- Glyoxylate cycle, 136b
- GMP
catabolism, 152, 156f
cGMP, 144, 145f, 162
from guanine, 156, 157f
from inosine 5'-monophosphate, 152, 154f
- Goldstein, Joseph, 124–125
- Gout, 157b
- G-protein-coupled receptors, 88, 164, 164f
- GPXs (glutathione peroxidases), 74f, 75, 80–82, 82f
- Growth factors
glycosylation of, 186–187
signaling, 169–170, 171f
- GRXs (glutaredoxins), 76
- GSH (glutathione), 65, 66, 81, 129, 144
- GSH peroxidases, 51
- GSH reductase, 81
- GSSG (disulfide glutathione), 76, 81, 82f
- GTP, 41, 42f, 55, 113, 152
- GTPase, 119, 217
- Guanine, 148, 149f, 156, 157f. *See also* Purines
- Guanylate kinase, 152, 154f
- H
- H⁺, and proton motive force, 39, 46–51, 47f
- Harman, Denham, 83b
- Hedgehog, 119
- Hedgehog acyltransferase, 119
- Heme, 19, 43, 44f, 129, 131f
- Henseleit, Kurt, 134, 136b
- Hexokinase, 25f, 26, 31–32, 33f, 88, 94, 169, 207
- Hexosamine pathway, 26, 27f, 35, 87
glyconjugate generation, 98–99, 99f
in proliferating cells, 190
- Hexose monophosphate shunt. *See* Pentose phosphate pathway
- HGPRT (hypoxanthine-guanine phosphoribosyltransferase), 155, 157b, 157f
- HIF (hypoxia-inducible factor), 76, 138, 169, 177–180, 178f–179f, 197, 202, 204–205, 204f
- HIG-1 (hypoxia-inducible gene-1), 52
- High-fructose corn syrup, 100
- Hill, Archibald Vivian, 24b
- Histone demethylases, 142
- Histone methyltransferases, 128, 142
- Histones, 142, 183, 184
- HMG-CoA reductase (3-hydroxy-3-methylglutaryl CoA reductase), 105, 121–125, 122f, 173
- Homocysteine, 142, 143f, 185, 186f
- Homolactic fermentation, 31
- Hyaluronic acid, 100
- Hydrogen isotope tracing, 228–230
- Hydrogen peroxide, 51–52, 65, 74–78, 74f, 75f, 77f, 79f, 80–81
- Hydrogen-peroxide-dependent signaling, 75, 75f
- Hydroperoxides, 80, 81
- 3-Hydroxyacyl-ACP dehydratase, 107, 109f
- 2-Hydroxyglutarate, 5, 204f, 205, 221, 226
- Hydroxyl radical, 74, 74f, 75
- 3-Hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase), 105, 121–125, 122f, 173
- Hydroxymethyltransferase, 129, 130f
- 5-Hydroxytryptophan, 138–139, 140f
- Hyperpolarization of ¹²C, 230–231
- Hypoxanthine, 148, 152, 156f, 157b
- Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), 155, 157b, 157f
- Hypoxia-inducible factor (HIF), 76, 138, 169, 177–180, 178f–179f, 197, 202, 204–205, 204f
- Hypoxia-inducible gene-1 (HIG-1), 52
- I
- Ignarro, Louis J., 144
- Immunity, metabolic links to, 215

- IMP dehydrogenase, 152, 155f
Inflammation, metabolic links to, 215
Inosine 5'-monophosphate, 151–152, 153f–155f
Insulin, 32, 97b, 168, 208b–209b
Insulin resistance, 101b
Isocitrate, 70, 71f
Isocitrate dehydrogenase (IDH)
 IDH1, 4–5, 65, 70, 71f
 IDH2, 4–5, 60, 60f, 65, 70, 71f, 203
 IDH3, 70, 71f
 mutations, 4–5, 204f, 205, 206–207, 220–221, 226
 NADPH generation, 65, 70, 71f
 in TCA cycle, 41, 42f, 45–46
Isopentenyl pyrophosphate, 121, 122f
Isotope carbon-labeling techniques, 5
Isotope tracing, 224, 226–231, 228f
- J**
- Johnson, William, 39
Joule (J), 11
Jumonji-domain (JmjC) histone demethylase enzymes, 203–204, 204f, 205
- K**
- Kelch-like ECH-associated protein 1 (KEAP1), 203, 204
Ketone bodies, 116b–117b, 116f
Kinases, 76
Kinetic energy, 10–11
Kinetics, enzyme, 19
Kornberg, Arthur, 150
Kornberg, Hans, 136b
K-*ras* oncogene, 194, 200
Krebs, Hans, 6, 39, 42, 134, 136b
Krebs cycle. *See* TCA cycle
- L**
- Lactase, 23, 88
Lactate
 converted to pyruvate, 90, 92b, 93, 192
 pyruvate conversion to, 17b–18b, 23, 30f, 31, 31f, 202
 release/uptake, 192
Lactate dehydrogenase, 17b, 30–31, 30f, 31f, 93, 179–180, 192, 231
Lactic acidosis, 62
Lactose, 23, 87f
Lactose intolerance, 88
- Lane, Andrew, 229
Lane, Nick, 37
Lanosterol, 123–124
L-arginine, 144, 145f
Law of mass action, 14
LDL (low-density lipoprotein), 124–125
L-DOPA, 139–140, 141f
Le Chatelier's principle, 14
Leigh syndrome, 62
Leloir, Luis Federico, 88f
Leloir pathway, 88–89, 88f
Lesch-Nyhan syndrome, 157b
Leukotrienes, 120
Linoleic acid, 105, 106f
Lipids, 103–125
 cholesterol, synthesis and regulation of, 120–125, 122f
 ketone body production with fasting, 116b–117b, 116f
 overview of metabolism, 104f
 production of, 105–110, 108f–109f, 111f
 quick guide to, 103–105
 regulation of fatty acid anabolism and catabolism, 113, 115, 115f, 117
 roles in body, 103
 signaling pathway activation by, 105, 117–120, 119f
 structure, 106f
Lipins, 110
Liver
 fructose metabolism in, 100b–101b, 101f
 nonalcoholic fatty liver disease, 230
LKB1, 200
Lohman, Karl, 24b
Lovastatin, 124b
Low-density lipoprotein (LDL), 124–125
L-tryptophan hydrolase, 138, 140f
Lustig, Robert H., 100b
Lysine, acetylation of, 2, 183
Lysine-specific demethylases, 185, 187f
Lysosomes, 175, 175f
- M**
- Macroautophagy, 175–176
Magnetic resonance spectroscopy (MRS), 226
Malaria, 70b
Malate
 citrate transporter and, 53, 55f
 conversion to pyruvate, 71, 72f, 192
 fumarate conversion to, 136
 in NADPH generation, 70–71, 72f
 oxaloacetate conversion to, 93

- Malate-aspartate shuttle, 53, 54f, 136
Malate dehydrogenases, 41, 42f, 53, 54f, 93, 107, 108f, 136
Malic enzymes, 56f, 66, 71, 72f, 107, 108f, 192, 194
Malonyl-CoA, 107–108, 109f, 110, 117
Malonyl transacylase, 107
Maltose, 87f
Mammalian target of rapamycin (mTOR), 2
MAPK (mitogen-activated protein kinase), 164–165
Mass action, law of, 14
Mass-action ratio, 15
Mass spectroscopy (MS), 224–229, 231
MAX protein, 169
MCU (mitochondrial calcium uniporter), 58, 59f
Melanins, 140–141, 141f
MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes), 62
Melatonin, 129, 139, 140f
Membrane potential, 49
Metabolic disease, screening for, 225–226
Metabolic flux
 factors controlling, 22
 illustration of control, 21
 increase in cancer cells and proliferating cells, 35
 isotope tracers to quantify, 229–231
 in TCA cycle, control of, 45
Metabolic flux analysis, 224, 229–231
Metabolic pathways. *See also specific pathway*
 amphibolic, 41
 analyzing, 223, 226–229
 conserved, 212
 direction of, 9–10
 enzyme catalysis in, 9–10, 13, 18–20
 factors controlling metabolic flux, 22
 illustration of control of flux through, 21
 metabolic flux analysis, 224, 229–231
 NAD⁺-generating, 183, 185f
 overview, 5–6, 6f
Metabolic switches, 212
Metabolism
 aging and, 212
 analyzing, 223–231
 essential functions of cells, 9, 10f
 integration with diet and environment, 211–212
 introduction to, 1–7
 reciprocal control of metabolism and cellular decisions, 216
 as therapeutic target in cancer, 206–209, 220–221
Metabolism research, future pathways of, 211–221
Metabolites
 control of metabolic flux of pathways by, 21–22, 45
 defined, 9
 intracellular metabolite control of signaling, 181–188, 182f, 184f–187f
 measuring, 223–226
 oncometabolites, 226
 regulation of glycolysis, 32, 33f, 34
 regulation of TCA cycle, 45
 TCA cycle provision of, 43
Metabolomics, 214, 223, 225–226, 231
Metal ions, as cofactors, 19
Metformin, 2, 208b–209b, 208f
Methionine, 72, 128, 142–144, 143f, 185, 186f
Methionine adenosyltransferase, 142, 143f
Methionine synthase, 142, 143f
Methotrexate, 160, 206
Methylation, 4, 184–185, 186f
5-Methyl-tetrahydrofolate, 142, 143f
Methyltransferases, 142, 143f, 184–185, 186f
Mevalonate, 121
Meyerhof, Otto Fritz, 24b
Michaelis–Menten constant (K_m), 19–20
Michaelis–Menten equation, 19
Microautophagy, 175
Microbiome, 212
Mitchell, Peter, 46, 48b, 51
Mitochondria, 37–63
 ATP production in, 23, 26, 38–39, 41
 calcium homeostasis regulation, 57–58, 59f
 cells with none or few, 29, 68
 degradation of, 51
 disease and, 62–63
 dynamics, 61
 electron transport chain (*see* Electron transport chain)
 energy-generating capacity of, 38–41
 quick guide to, 38–39
 TCA cycle and, 39–41, 40f, 42f
 essential features of, 38
 evolutionary origin of, 37
 fission and fusion, 61
 heme synthesis, 129, 131f
 metabolism in proliferating cells, 190, 191f, 192–193
 nuclear gene expression controlled by metabolic signals, 217–218
 oxidative phosphorylation in, 38, 39, 46–51, 47f
 oxygen consumption, 49, 50b
 ROS in, 51–52
 as signaling organelles, 5, 38, 61–62
 structure, 38, 40f

- TCA cycle (*see* TCA cycle)
transporters, 38, 52–54, 54f–56f, 58, 59f, 107, 111–113, 112f, 192
uncoupling biosynthetic activity from
 ATP-generation, 58–60, 60f
 urea cycle (*see* Urea cycle)
- Mitochondrial antiviral-signaling protein, 61
Mitochondrial calcium uniporter (MCU), 58, 59f
Mitochondrial DNA (mtDNA), 38, 61, 62
Mitochondrial permeability transition pore (MPTP), 58
Mitogen-activated protein kinase (MAPK), 164–165
Mitophagy, 51
Moncada, Salvador, 144
Mondo transcription factors, 180–181, 180f
Monocarboxylate transporters, 192
Monosaccharides, 85, 87. *See also* Simple sugars
Monounsaturated fatty acids, 105, 106f
MPTP (mitochondrial permeability transition pore), 58
MS (mass spectroscopy), 224–229, 231
mtDNA (mitochondrial DNA), 38, 61, 62
mTOR, 169–170, 171f, 172b, 199
mTORC1 (rapamycin complex 1), 168f, 169–170, 171f, 173, 177, 179
mTORC2 (rapamycin complex 2), 169–170
Murad, Ferid, 144
Muscle cells, purine nucleotide cycle in, 156–157
Mutations, IDH, 4–5, 204f, 205, 206–207, 220–221, 226
MYC protein, 169, 199f, 200
Myoadenylate deaminase, 157
Myristoylation, 118–119, 119f
- N**
- N*-acetylgalactosamine (GalNAc), 97–98
N-acetylglucosamine (GlcNAc), 97–100
N-acetylglucosamine 1-phosphate, 98
N-acetylglucosamine 6-phosphate, 98
NAD⁺
 as coenzyme, 19, 41
 deacetylation and, 183–184, 184f
 generated by malate dehydrogenase 1, 93, 107, 108f
 metabolic pathways generating, 183, 185f
 in proliferating cells, 190, 192
 regeneration, 30–31, 30f, 31f
 transport out of mitochondria, 30
NADH
 ATP amount generated in oxidation by ETC, 51, 55
 coupled redox reactions, 16, 17b–18b
 electron transport chain and, 39, 40f, 46, 47f, 49, 51
 generated
 in fatty acid oxidation, 113, 114f
 in glycolysis, 23, 25f, 26
 by lactate generation from pyruvate, 93
 in TCA cycle, 39, 41, 42f
 inhibition of TCA cycle by, 45, 45f
 oxidation to NAD⁺, 30, 46, 47f, 49, 107, 108f
 respiratory rate control by, 57
 transport into mitochondria, 30, 53, 54f
NADH dehydrogenase, 39, 46
NADPH, 65–83
 in citrate formation, 60, 60f
 coupled reactions, 16, 105, 110
 fatty acid synthesis, 105, 107, 110
 generation
 by isocitrate dehydrogenase, 65, 70, 71f
 by malic enzymes, 66, 71, 72f, 107, 108f, 194
 by one-carbon metabolism, 66, 72–74, 73f
 overview, 65–66, 66f
 by pentose phosphate pathway, 65–66, 67f, 68, 69f, 70b
 by TCA-cycle intermediates, 70–71, 71f, 72f
 in proliferating cells, 189–190, 189f, 194
 quick guide to, 65–66, 66f
 roles in metabolism, 65–66, 66f
 ROS detoxification, 79–82
NADPH/NADP⁺ ratio, 65
NADPH oxidases (NOXs), 65, 66, 74f, 76, 78, 79f, 198
Nernst equation, 18b
Neurons, glycolysis control in, 68
Neurotransmitters, 129, 138–140, 139f–141f
Nicotinamide, 183
Nicotinamide mononucleotide, 183
Nicotinamide phosphoribosyltransferase, 183
Nitric oxide, 144, 145f
Nitric oxide synthases, 129, 144, 145f
Nitrogen bases, 148–150, 149f
Nitrogen isotope tracing, 229
NMR (nuclear magnetic resonance) spectroscopy, 224–225, 227–229
N-myristoylation, 118–119, 119f
Nobel Prize, metabolism-related, 1, 3b–4b
Nonalcoholic fatty liver disease, 230
Noncompetitive inhibition, 20–21, 21f
Non-small cell lung cancer, 206
Nonsteroidal anti-inflammatory drugs (NSAIDs), 120
Norepinephrine, 140, 141f, 142
NOXs (NADPH oxidases), 65, 66, 74f, 76, 78, 79f, 198

- N*-palmitoylation, 119, 119f
NRF2 (nuclear factor erythroid 2-related factor 2), 81, 203, 207
NSAIDs (nonsteroidal anti-inflammatory drugs), 120
Nuclear factor erythroid 2-related factor 2 (NRF2), 81, 203, 207
Nuclear factor NF- κ B, 76
Nuclear magnetic resonance (NMR) spectroscopy, 224–225, 227–229
Nucleosides, 148, 149f, 150
Nucleotides, 147–165
 deoxyribonucleotides, 150–151, 150f
 overview of metabolism, 147f
 purine biosynthesis, 151–152, 153f–155f
 purine degradation, 152, 156f
 purine salvage, 155–157, 157f–158f
 pyrimidine biosynthesis, 158–160, 159f
 pyrimidine catabolism, 160–162, 163f
 quick guide to, 148
 signaling and, 162, 164–165, 164f
 structure, 148–150, 149f
Nutrient sensing, 216–217
Nutrient uptake
 in proliferating cells, 194–195, 195f
 signal transduction regulation of, 168–169, 168f
- O**
- Obesity, 90, 100b, 103
Ochoa, Severo, 150
O-GlcNAcase, 99
O-GlcNAc transferase (OGT), 97, 99, 99f
Oleic acid, 105, 106f
OMP decarboxylase, 162f
Oncogenes, 197, 202–203, 219
Oncometabolites, 226
One-carbon metabolism
 fueled by serine, 205
 NADPH generation in, 66, 72–74, 73f
 in proliferating cells, 190, 191f
Organic cation transporters, 209b
Ornithine, 130, 132f, 134, 136b, 137f
Ornithine aminotransferase, 130, 132f
Ornithine transcarbamoylase, 134, 137f
Orotate, 158, 159f
Oxaloacetate, 39, 41, 42f, 43–45, 43f, 59, 60f
 from citrate, 43, 53, 56f, 59, 60f, 107, 108f
 citrate conversion to, 71, 72f
 conversion to malate, 71, 93
 conversion to PEP, 93, 93f
 malate conversion to, 136
 pyruvate conversion to, 44, 45, 90, 93–94, 93f
Oxidation reaction, 2, 16. *See also specific reactions*
Oxidation-reduction (redox) reactions, 16, 17b–18b. *See also specific reactions*
Oxidative damage, 75
Oxidative phosphorylation, 38, 39, 46–51, 47f
Oxidative stress, in red blood cells, 68, 70b
Oxidative stress-induced cell death, 198
Oxidoreductin 1 (ERO1), 78, 80f
Oxygen
 as final electron acceptor in ETC, 46, 47f
 levels and epigenetics, 186
 mitochondrial/cellular consumption, 49, 50b, 56, 178
 reactive oxygen species (*see* ROS)
 transcriptional network regulation, 177–180, 178f–179f
Oxygen conformance, 178
- P**
- Palmitate, 103, 104f, 105, 110, 113, 115
Palmitoylation, 118–119, 119f
Palmitoyl-CoA, 113, 114f–115f, 115, 120
Paracoccus denitrificans, 37
Parkin, 51
Parkinson's disease, 58, 140, 165b
Parnas, Jakub, 24b
Pasteur, Louis, 31
Pasteur effect, 31
PDI (protein disulfide isomerase), 78, 80f
Pentose phosphate pathway
 galactose entry into, 89
 glycolytic intermediates and, 26, 27f, 35
 NADPH generation, 65–66, 67f, 68, 69f, 70b
 in proliferating cells, 190, 191f
PEPCK (phosphoenolpyruvate carboxykinase), 93, 94f
Peroxiredoxins (PRXs), 51, 74f, 75, 80–82, 81f, 209
PET (positron emission tomography), 34, 34f
Peutz-Jeghers syndrome, 200
PFK1 (phosphofructokinase-1), 25f, 26, 31–32, 33f, 34, 94, 95, 96f, 97b, 100b
PFK2 (phosphofructokinase-2), 32, 33f, 95, 97b
Phenomenalins, 41
Phenotype, metabolism and, 1–2
Phenylalanine, 129, 141f, 142, 225
Phenylalanine hydroxylase, 129, 141f, 142
Phenylketonuria (PKU), 142, 225
Phosphatases, 76, 92b
Phosphate dehydrogenase, 77
Phosphate transporter, 53

- Phosphatidic acid, 110, 111f
Phosphatidic acid phosphohydrolases, 110, 111f
Phosphatidylinositol 4,5-bisphosphate, 120, 169
Phosphatidylinositol 3,4,5-trisphosphate, 120, 169
Phosphoacetylglucosamine mutase, 98, 99f
Phosphodiesterase type 5, 144, 145f
Phosphoenolpyruvate, 29, 43–44, 43f, 90, 93, 93f
Phosphoenolpyruvate carboxykinase (PEPCK), 93, 94f
Phosphofructokinase-1 (PFK1), 25f, 26, 31–32, 33f, 34, 94, 95, 96f, 97b, 100b
Phosphofructokinase-2 (PFK2), 32, 33f, 95, 97b
6-Phosphofructo-2-kinase, 68
Phosphoglucomutase, 88, 88f
6-Phosphogluconate dehydrogenase, 67f, 68
Phosphogluconate pathway. *See* Pentose phosphate pathway
3-Phosphoglycerate, 25f, 26, 27f, 29, 129, 130f
Phosphoglycerate dehydrogenase, 129, 130f, 204f, 205
3-Phosphohydroxypyruvate, 129, 130f
Phosphoinositide-dependent kinase 1, 169
Phosphoinositide 3-kinase, 168f, 169
Phosphoinositides, 119f, 120
Phospholipase A2, 120
Phospholipase C, 120
Phospholipids, 105, 106f
5-Phosphoribosyl-1-pyrophosphate (PRPP), 151–152, 153f, 155–156, 155f, 157b, 157f, 158, 159f, 160, 162f
Phosphorylation
 oxidative, 38, 39, 46–51, 47f
 substrate-level, 26, 29
3-Phosphoserine, 129, 130f
Phosphoserine phosphatase, 129, 130f
Phosphoserine transaminase, 129, 130f
PI3K, 197, 199–200, 199f, 208b
PKA (protein kinase A), 95, 97b
PKU (phenylketonuria), 142, 225
Polyunsaturated fatty acids, 105, 106f
Porcupine, 119
Porins, 39
Porphyrins, 43, 44f
Positron emission tomography (PET), 34, 34f
Posttranslational modifications, 167, 181–187, 182f, 218
 acetylation, 181–183, 184f
 deacetylation, 183–184, 184f
 demethylation, 185–186
 glycosylation of, 186–187
 by lipids, 105, 117–119, 119f
 methylation, 184–185, 186f
 N-myristoylation, 118–119, 119f
 N-palmitoylation, 119, 119f
 S-palmitoylation, 118–119, 119f
 S-prenylation, 119, 119f
Potential energy, 10–11
P2 purinoreceptors, 162, 164, 164f
Prokaryotes, endosymbiont theory and, 37
Proliferating cells, metabolism of, 189–209, 216
 aberrant activation of signaling pathways, 197–203, 198f–199f, 201f
 NADPH, 194
 nutrient uptake, 194–195, 195f
 overview, 189–190, 189f
 T cells, 195–197, 196f
Proline dehydrogenase, 77
Prolyl hydrolases, 177, 178f, 203, 205
Prostaglandins, 120
Prostate cancer, 231
Prosthetic groups, 19
Protein disulfide isomerase (PDI), 78, 80f
Protein kinase A (PKA), 95, 97b
Protein kinase C, 120
Proteins
 amino acids (*see* Amino acids)
 posttranslational modifications, 167, 181–187, 182f
Proteoglycans, 99–100
Proton gradient, 46–48, 47f
Proton leakage, 49–50, 57
Proton motive force (pmf), 39, 46–51, 47f
Protonophore, 49–50, 50b, 58
Proton pumps, 39, 46–51, 47f
PRPP (5-phosphoribosyl-1-pyrophosphate), 151–152, 153f, 155–156, 155f, 157b, 157f, 158, 159f, 160, 162f
PRPP synthetase, 157b
PRXs (peroxiredoxins), 51, 80–82, 81f
PTEN, 199, 199f
PTEN-induced putative kinase 1, 51
p53 transcription factor, 200
Purines, 43
 biosynthesis, 151–152, 153f–155f
 caffeine, 165b
 catabolism, 152, 156f
 salvage, 155–157, 157f–158f
 structure, 148–150, 149f
Pyrimidines, 43
 biosynthesis, 158–160, 159f
 catabolism, 160–162, 163f
 regulation of synthesis, 160, 162f
 structure, 148–150, 149f
Pyrroline-5-carboxylate reductase, 131, 132f
Pyruvate
 acetyl-CoA from, 39, 41, 42f, 45, 45f

- Pyruvate (*Continued*)
 alanine conversion to, 93
 alanine from, 26, 134
 conversion to glucose, 28
 conversion to lactate, 17b–18b, 23, 30f, 31, 31f, 202
 conversion to oxaloacetate, 44, 45, 90, 93–94, 93f
 entry into mitochondria, 23, 26, 29, 30, 53, 192
 from glycolysis, 23, 25f, 26, 29
 lactate conversion to, 90, 92b, 93, 192
 malate conversion to, 71, 72f, 192
Pyruvate carboxylase, 44, 45, 45f, 90, 93, 93f
Pyruvate decarboxylase, 31f
Pyruvate dehydrogenase, 39, 41, 45, 45f, 54, 77, 179–180, 192
Pyruvate dehydrogenase kinase, 179–180
Pyruvate kinases, 5, 25f, 26, 31–32, 33f, 34, 200–202, 201f
Pythagoras, 70b
- R**
- Radioisotopes, 226–227
Rag GTPase, 170, 217
Rapamycin, 169–170, 171f, 172b
Rapamycin complex 1 (mTORC1), 168f, 169–170, 171f, 173, 177, 179, 216–217
Rapamycin complex 2 (mTORC2), 169–170
Ras, 119, 121, 169
Ras homolog enriched in brain (RHEB), 170
Reactions
 coupled, 15–16, 15f, 17b–18b
 direction, 9–10, 27
 energy change in, 9–16
 equilibrium constant (K_{eq}), 14–15
 Michaelis–Menten constant (K_m), 19–20
 rate, 13, 18–20, 20f
Reactive oxygen species. *See* ROS
Receptor tyrosine kinases, 168–169, 168f
Redox balance in cancer cells, 197, 198, 198f
Redox signaling, 74–78, 75f, 214
Reduction potential, 17b, 46
Reduction reaction, 16. *See also specific reactions*
Respiration, 10–11
 coupled, 49, 50b
 uncoupled, 49–50, 50b
Respiratory chain. *See* Electron transport chain
RHEB (Ras homolog enriched in brain), 170
Rheb GTPase, 217
Ribonucleotide reductase, 150f, 151, 160, 161f
Ribonucleotides, 151
Ribose 5-phosphate, 89, 152, 153f, 155f
Ribozyyme, 18
Ribulose 5-phosphate, 66, 67f, 68, 69f
Rickettsia prowazekii, 37
RNA, 18, 148, 150
ROS, 2, 65, 214–215
 in cancer cells, 197, 198, 198f, 207, 209
 detoxification by NADPH, 79–82
 generation by electron transport chain, 51–52, 179–180
 in hypoxia, 179–180
 pathology and, 82–83
 sources of, 74, 74f, 76–78, 77f, 79f, 80f
 stress signaling, 218
 targets of, 76
 T-cell activation and proliferation, 196
 thio-dependent redox signaling, 74–78, 75f
- S**
- S-adenosylhomocysteine (SAH), 142, 143f, 185, 186f
S-adenosylmethionine (SAM), 142, 143f, 184–185, 186f
Saturated fatty acids, 105, 106f
SCAP, 123
Sehgal, Suren, 172b
Serine, 72–73, 73f
 one-carbon metabolism fueled by, 190, 205
 3-phosphoglycerate converted to, 26
 production of, 129, 130f, 190
 sphingolipids production from, 120
Serotonin, 129, 138–139, 140f
Serotonin *N*-acetyltransferase, 139, 140f
Signaling, 1–2, 9, 167–188
 aberrant activation of signaling pathways in proliferating cells, 197–203, 198f–199f, 201f
 AMPK induction of catabolism, 172–173, 173f–174f
 autophagy, 167, 174–177, 175f–176f
 carbohydrates and, 87, 97–100
 growth factor, 169–170, 171f
 hydrogen peroxide-dependent, 75, 75f
 intracellular metabolite control of, 181–188, 182f, 184f–187f
 lipids, signaling pathway activation by, 105, 117–120, 119f
 mitochondria as signaling organelles, 5, 38, 61–62
 mTOR and, 169–170, 171f, 172b
 nuclear gene expression controlled by metabolic signals, 217–218
 nucleotides and, 162, 164–165, 164f

- nutrient uptake, regulation of, 168–169, 168f
 - redox, 74–78, 75f, 214
 - thio-dependent redox signaling, 74–78, 75f
 - transcriptional network regulation, 177–181, 178f–180f
 - Simple sugars, 23, 85
 - in glycoproteins, 98
 - metabolism of, 87–90, 87f–89f
 - sweetness, 88
 - Sirtuin family of deacetylases, 183–184, 184f
 - SLC25A1 transporter, 53, 56f
 - SNAT transporters, 194, 195f
 - S-nitrosothiol, 144, 145f
 - Sodium-glucose transporters, 194, 195f
 - SODs, 51, 74, 77–78, 77f, 80
 - Solute carrier family of transporters, 194–195, 195f
 - S-palmitoylation, 118–119, 119f
 - Sphingolipids, 119f, 120
 - Sphingosine 1-phosphate, 120
 - S-prenylation, 119, 119f
 - Squalene, 121, 122f
 - SREBP, 123–125
 - Stable isotopes, 227, 230
 - Standard free-energy change, 14
 - Starch, 85
 - Statins, 2, 124–125, 124b
 - Steric acid, 105
 - Stress signaling pathways, 218
 - Substrate-level phosphorylation, 26, 29
 - Succinate
 - GABA shunt generation of, 138, 139f
 - in TCA cycle, 41, 42f, 46
 - in tumorigenesis, 203–204
 - Succinate dehydrogenase, 39, 45, 46, 202–204, 204f
 - Succinic semialdehyde, 138, 139f
 - Succinic semialdehyde dehydrogenase, 138, 139f
 - Succinyl-CoA, 41, 42f, 43, 43f, 45, 129, 131f
 - Sucrase, 23, 87–88
 - Sucrose, 23, 87f
 - Sulfenic acid, 76
 - Sulfenic–amide bond, 76
 - Sulfinic acid, 76
 - Sulfonic acid, 76
 - Superoxide, 51–52, 65, 66, 74–75, 74f, 77–78, 77f, 79f
 - Sweeteners, artificial, 101b
 - Sweetness, of simple sugars, 88
- T**
- TCA cycle
 - as amphibolic pathway, 41
 - anaplerosis, 43–44
 - as biosynthetic hub, 42–44, 43f
 - biosynthetic intermediates generated by, 58–60, 60f
 - discovery of, 39, 41
 - Gibbs free energy and, 41, 44–45
 - glycolysis regulation by intermediates, 32, 34
 - lipid synthesis and, 105, 111f
 - overall reaction, 41
 - overview, 39, 41, 42f
 - in proliferating cells, 191f, 192–193, 196
 - regulation of, 44–46, 45f
 - TCA-cycle intermediates
 - amino acids converted to, 132, 133f
 - amino acids generated from, 129–130, 131f
 - NADPH generation, 70–71, 71f, 72f
 - production from purine nucleotide salvage, 156–157, 158f
 - in proliferating cells, 192–193
 - T cells, 195–197, 196f, 229
 - TET (ten-eleven translocation) DNA hydrolases, 203, 204f, 205
 - Tetrahydrofolate (TFH), 73, 73f, 129, 130f, 142, 143f, 152, 160, 161f
 - Thermodynamics, 10–11
 - Thio-dependent redox signaling, 74–78, 75f
 - Thioesterase, 107, 109f
 - Thiolate anion, 76
 - Thioredoxin (TRX), 65, 66, 76, 80, 81f
 - Threonine, 185, 193
 - Threonine dehydrogenase, 185
 - Thromboxanes, 120
 - Thymidylate synthase, 160, 161f
 - Thymine, 149f, 150. *See also* Pyrimidines
 - Toll-like receptor signaling, 61–62
 - Transaldolase, 68
 - Transcriptional network regulation, 177–181, 178f–180f
 - by glucose, 180–181, 180f
 - by oxygen, 177–180, 178f–179f
 - Transition state, 13, 13f
 - Transketolase, 68
 - Transporters. *See also specific transporters*
 - calcium, 58, 59f
 - carnitine-acylcarnitine translocase, 103, 112f, 113
 - citrate, 192
 - cystine, 144
 - fructose, 100b
 - glucose (GLUTs), 194, 195f
 - glutamine and glutamate, 194–195, 195f
 - mitochondrial, 38, 52–54, 54f–56f, 58, 59f, 107, 111–113, 112f, 192
 - monocarboxylate, 192

- Transporters (*Continued*)
 nutrient, 194–195, 195f
 organic cation transporters, 209b
 pyruvate, 5, 38, 192
 sodium-glucose, 194, 195f
 solute carrier family, 194–195, 195f
trans-sulfuration, 142, 143f
Triacylglycerols (triglycerides), 100b–101b, 101f,
 103, 105, 106f, 110
Tricarboxylic cycle. *See* TCA cycle
Triose kinase, 89f, 90
Triparanol, 124b
TRX (thioredoxin), 65, 66, 80, 81f
TRX reductase (TR1 or TR2), 76, 80, 81f
Tryptophan
 metabolism, 129
 serotonin generation from, 138–139,
 140f
Tuberous sclerosis 1 and 2, 170
Tumor-initiating cells, 206
Tumor suppressors, 197, 202–203, 219
Tyrosinase, 41
Tyrosine
 maintenance of levels within cells,
 141–142
 metabolism, 128, 139–142, 141f
 from phenylalanine, 129, 141f, 142
Tyrosine hydroxylase, 139–140, 141f
- U**
- Ubiquinol, 46
Ubiquinone (Q), 39, 46, 52
UDP-galactose 4-epimerase, 99
UDP-glucose, 95, 98f
UDP-glucose pyrophosphorylase, 95, 98f
UDP-*N*-acetylgalactosamine, 99, 99f
UDP-*N*-acetylglucosamine, 99, 99f, 187
UDP-*N*-acetylglucosamine pyrophosphatase, 99,
 99f
ULK1, 177
Uncoupled respiration, 49–50, 50b
Unsaturated fatty acids, 105, 106f, 107
Uracil, 149f, 150. *See also* Pyrimidines
Urea cycle, 131–136, 133f, 135f, 136b, 137f
Uric acid, 152, 156f, 157b
Uridine nucleotides, generation of, 160, 161f
- V**
- Viagra, 144
Vicine, 70b
Vitamin C, 82
Voltage-dependent anion channel (VDAC), 39, 53,
 77
von Hippel-Lindau tumor suppressor (VHL), 177,
 178f
- W**
- Wang, Thomas, 225
Warburg, Otto, 34, 136b, 190, 220
Warburg effect, 34–35, 92b, 190, 231
Watson, James, 147
Wilkins, Maurice, 147
Williams, G.R., 55
Wnt, 119
- X**
- Xanthine, 148, 152, 156f, 157b
- Y**
- Yeast, fermentation in, 31, 31f